RxDoctor Payments Data

Thomas Zweifel, DO

Neurology · Sheboygan, WINPI 1114027307

Payments from drug & device makers

$341in general payments, 2019–2025

Across 12 payments — averaging $28.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$146
  • AbbVie$70
  • Jazz Pharmaceuticals Inc.$37
  • Acorda Therapeutics, Inc$24
  • Teva Pharmaceuticals USA, Inc.$21
  • E.r. Squibb & Sons, L.L.C.$19
  • plus $23 from 2 others

What the payments were for

  • Speaking & faculty fees$247%
  • Food & beverage$29887%
  • Education$196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$341 in reported general payments places this provider in the 50th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$123,640
Medicare patients
220
Services billed
9,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine18$152,372
EpidiolexCannabidiol (Cbd)33$63,043
UbrelvyUbrogepant32$50,793
Aimovig AutoinjectorErenumab-Aooe32$27,324
Emgality PenGalcanezumab-Gnlm37$26,423
QuliptaAtogepant20$22,677
Nurtec OdtRimegepant Sulfate11$15,381
Levetiracetam250$9,967
Carbamazepine70$7,292
Sumatriptan Succinate73$6,386
Tegretol XrCarbamazepine18$5,145
Lamotrigine106$4,616
Carbidopa-LevodopaCarbidopa/Levodopa156$4,334
Carbidopa-Levodopa ErCarbidopa/Levodopa54$3,959
Carbamazepine ErCarbamazepine37$3,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$21$152,37218 claims
AbbVieUbrelvy, Qulipta$70$73,47052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 308 neurology providers in Wisconsin.

Other neurology in Sheboygan

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →